REGENXBIO Inc. (RGNX)

Market Cap	392.17M
Revenue (ttm)	83.33M
Net Income (ttm)	-227.10M
Shares Out	50.09M
EPS (ttm)	-4.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	370,026
Open	7.90
Previous Close	7.91
Day's Range	7.70 - 7.96
52-Week Range	5.62 - 21.57
Beta	1.35
Analysts	Strong Buy
Price Target	32.89 (+320.05%)
Earnings Date	Mar 13, 2025

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 17, 2015
• Employees: 353
• Stock Exchange: NASDAQ
• Ticker Symbol: RGNX
• Website: https://www.regenxbio.com

Financial Performance

In 2024, REGENXBIO's revenue was $83.33 million, a decrease of -7.66% compared to the previous year's $90.24 million. Losses were -$227.10 million, -13.81% less than in 2023.

Analyst Forecast

According to 9 analysts, the average rating for RGNX stock is "Strong Buy." The 12-month stock price forecast is $32.89, which is an increase of 320.05% from the latest price.

Price Target

$32.89

(320.05% upside)

Analyst Consensus: Strong Buy